

Dominick J Angiolillo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1653605/publications.pdf>

Version: 2024-02-01

574
papers

40,836
citations

2538

96
h-index

3394

183
g-index

630
all docs

630
docs citations

630
times ranked

18333
citing authors

#	ARTICLE	IF	CITATIONS
1	2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <i>European Heart Journal</i> , 2021, 42, 1289-1367.	1.0	3,048
2	Standard- vs High-Dose Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary Intervention. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 1097.	3.8	1,185
3	Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to Adenosine Diphosphate. <i>Journal of the American College of Cardiology</i> , 2010, 56, 919-933.	1.2	1,058
4	Variability in Individual Responsiveness to Clopidogrel. <i>Journal of the American College of Cardiology</i> , 2007, 49, 1505-1516.	1.2	886
5	Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention. <i>Circulation</i> , 2007, 116, 2923-2932.	1.6	831
6	Consensus and Update on the Definition of On-Treatment Platelet Reactivity to Adenosine Diphosphate Associated With Ischemia and Bleeding. <i>Journal of the American College of Cardiology</i> , 2013, 62, 2261-2273.	1.2	807
7	Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events. <i>New England Journal of Medicine</i> , 2013, 368, 1303-1313.	13.9	695
8	Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel—Thrombolysis in Myocardial Infarction 38. <i>Circulation</i> , 2008, 118, 1626-1636.	1.6	693
9	Ticagrelor with or without Aspirin in High-Risk Patients after PCI. <i>New England Journal of Medicine</i> , 2019, 381, 2032-2042.	13.9	683
10	A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2012, 59, 2159-2164.	1.2	569
11	Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2019, 381, 1524-1534.	13.9	543
12	Platelet Inhibition with Cangrelor in Patients Undergoing PCI. <i>New England Journal of Medicine</i> , 2009, 361, 2318-2329.	13.9	533
13	Drug-eluting stent thrombosis. <i>Journal of the American College of Cardiology</i> , 2005, 45, 954-959.	1.2	505
14	Platelet Function Profiles in Patients With Type 2 Diabetes and Coronary Artery Disease on Combined Aspirin and Clopidogrel Treatment. <i>Diabetes</i> , 2005, 54, 2430-2435.	0.3	492
15	Randomized Comparison of a High Clopidogrel Maintenance Dose in Patients With Diabetes Mellitus and Coronary Artery Disease. <i>Circulation</i> , 2007, 115, 708-716.	1.6	435
16	Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation</i> , 2019, 140, 240-261.	1.6	428
17	Ticagrelor Compared With Clopidogrel by Geographic Region in the Platelet Inhibition and Patient Outcomes (PLATO) Trial. <i>Circulation</i> , 2011, 124, 544-554.	1.6	397
18	Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATElet inhibition and patient Outcomes (PLATO) trial. <i>European Heart Journal</i> , 2010, 31, 3006-3016.	1.0	389

#	ARTICLE	IF	CITATIONS
19	Bridging Antiplatelet Therapy With Cangrelor in Patients Undergoing Cardiac Surgery. JAMA - Journal of the American Medical Association, 2012, 307, 265-74.	3.8	386
20	Platelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary Intervention. Circulation, 2011, 124, 1132-1137.	1.6	381
21	ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. European Heart Journal, 2015, 36, 1252-1263.	1.0	366
22	Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y ₁₂ Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2019, 12, 1521-1537.	1.1	366
23	Randomized Comparison of Sirolimus-Eluting Stent Versus Standard Stent for Percutaneous Coronary Revascularization in Diabetic Patients. Circulation, 2005, 112, 2175-2183.	1.6	345
24	Inhibitory Effects of Ticagrelor Compared With Clopidogrel on Platelet Function in Patients With Acute Coronary Syndromes. Journal of the American College of Cardiology, 2010, 56, 1456-1462.	1.2	339
25	Impact of Platelet Reactivity on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. Journal of the American College of Cardiology, 2007, 50, 1541-1547.	1.2	335
26	Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. European Heart Journal, 2019, 40, 2632-2653.	1.0	335
27	Dosing Clopidogrel Based on CYP2C19 Genotype and the Effect on Platelet Reactivity in Patients With Stable Cardiovascular Disease. JAMA - Journal of the American Medical Association, 2011, 306, 2221-8.	3.8	313
28	Novel antiplatelet agents in acute coronary syndrome. Nature Reviews Cardiology, 2015, 12, 30-47.	6.1	299
29	Bleeding and stent thrombosis on P2Y ₁₂ -inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. European Heart Journal, 2015, 36, 1762-1771.	1.0	297
30	International Expert Consensus on Switching Platelet P2Y ₁₂ Receptor Inhibiting Therapies. Circulation, 2017, 136, 1955-1975.	1.6	293
31	Insulin Therapy Is Associated With Platelet Dysfunction in Patients With Type 2 Diabetes Mellitus on Dual Oral Antiplatelet Treatment. Journal of the American College of Cardiology, 2006, 48, 298-304.	1.2	284
32	ACC/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy. Journal of the American College of Cardiology, 2018, 72, 2915-2931.	1.2	273
33	Diabetes and Antiplatelet Therapy in Acute Coronary Syndrome. Circulation, 2011, 123, 798-813.	1.6	272
34	High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. European Heart Journal, 2004, 25, 1903-1910.	1.0	268
35	Differential Effects of Omeprazole and Pantoprazole on the Pharmacodynamics and Pharmacokinetics of Clopidogrel in Healthy Subjects: Randomized, Placebo-Controlled, Crossover Comparison Studies. Clinical Pharmacology and Therapeutics, 2011, 89, 65-74.	2.3	249
36	Basic Principles of Platelet Biology and Clinical Implications. Circulation Journal, 2010, 74, 597-607.	0.7	239

#	ARTICLE	IF	CITATIONS
37	Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. <i>European Heart Journal</i> , 2009, 30, 1753-1763.	1.0	226
38	Contribution of Gene Sequence Variations of the Hepatic Cytochrome P450 3A4 Enzyme to Variability in Individual Responsiveness to Clopidogrel. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 1895-1900.	1.1	214
39	Platelet thrombin receptor antagonism and atherothrombosis. <i>European Heart Journal</i> , 2010, 31, 17-28.	1.0	214
40	Intensifying Platelet Inhibition With Tirofiban in Poor Responders to Aspirin, Clopidogrel, or Both Agents Undergoing Elective Coronary Intervention. <i>Circulation</i> , 2009, 119, 3215-3222.	1.6	213
41	Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. <i>Circulation</i> , 2018, 138, 527-536.	1.6	211
42	Impact of Stent Deployment Procedural Factors on Long-Term Effectiveness and Safety of Sirolimus-Eluting Stents (Final Results of the Multicenter Prospective STLLR Trial). <i>American Journal of Cardiology</i> , 2008, 101, 1704-1711.	0.7	202
43	Impact of Chronic Kidney Disease on Platelet Function Profiles in Diabetes Mellitus Patients With Coronary Artery Disease Taking Dual Antiplatelet Therapy. <i>Journal of the American College of Cardiology</i> , 2010, 55, 1139-1146.	1.2	193
44	Consensus Document: Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. <i>Thrombosis and Haemostasis</i> , 2011, 106, 571-584.	1.8	188
45	Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1703.	3.8	186
46	Review article: Platelet abnormalities in diabetes mellitus. <i>Diabetes and Vascular Disease Research</i> , 2010, 7, 251-259.	0.9	184
47	A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. <i>European Heart Journal</i> , 2008, 29, 2202-2211.	1.0	183
48	Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. <i>Nature Reviews Cardiology</i> , 2018, 15, 480-496.	6.1	180
49	Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2732-2740.	1.2	179
50	Clopidogrel-Drug Interactions. <i>Journal of the American College of Cardiology</i> , 2011, 57, 1251-1263.	1.2	178
51	A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes Mellitus (OPTIMUS)-3 Trial. <i>European Heart Journal</i> , 2011, 32, 838-846.	1.0	178
52	Association of Proton Pump Inhibitor Use on Cardiovascular Outcomes With Clopidogrel and Ticagrelor. <i>Circulation</i> , 2012, 125, 978-986.	1.6	176
53	Pharmacodynamic Effects of Different Aspirin Dosing Regimens in Type 2 Diabetes Mellitus Patients With Coronary Artery Disease. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 180-187.	1.4	172
54	Increased Platelet Inhibition After Switching From Maintenance Clopidogrel to Prasugrel in Patients With Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1017-1023.	1.2	160

#	ARTICLE	IF	CITATIONS
55	Carboxylesterase 1 as a Determinant of Clopidogrel Metabolism and Activation. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 344, 665-672.	1.3	160
56	Impaired Responsiveness to the Platelet P2Y12 Receptor Antagonist Clopidogrel in Patients With Type 2 Diabetes and Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1005-1014.	1.2	155
57	Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. <i>Lancet</i> , The, 2019, 394, 1169-1180.	6.3	155
58	Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. <i>Thrombosis Research</i> , 2005, 115, 101-108.	0.8	154
59	Switching P2Y12-receptor inhibitors in patients with coronary artery disease. <i>Nature Reviews Cardiology</i> , 2016, 13, 11-27.	6.1	154
60	Long-Term Outcomes in Patients Undergoing Coronary Stenting on Dual Oral Antiplatelet Treatment Requiring Oral Anticoagulant Therapy. <i>American Journal of Cardiology</i> , 2008, 102, 1618-1623.	0.7	152
61	The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease. <i>Thrombosis and Haemostasis</i> , 2021, 121, 422-432.	1.8	149
62	Safety and Tolerability of Atopaxar in the Treatment of Patients With Acute Coronary Syndromes. <i>Circulation</i> , 2011, 123, 1843-1853.	1.6	147
63	Clopidogrel Withdrawal Is Associated With Proinflammatory and Prothrombotic Effects in Patients With Diabetes and Coronary Artery Disease. <i>Diabetes</i> , 2006, 55, 780-784.	0.3	146
64	P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials. <i>BMJ</i> , The, 2021, 373, n1332.	3.0	144
65	Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted?. <i>Journal of Invasive Cardiology</i> , 2004, 16, 169-74.	0.4	142
66	Validation of the Academic Research Consortium High Bleeding Risk Definition in Contemporary PCI Patients. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2711-2722.	1.2	139
67	Quantitative Magnetic Resonance Perfusion Imaging Detects Anatomic and Physiologic Coronary Artery Disease as Measured by Coronary Angiography and Fractional Flow Reserve. <i>Journal of the American College of Cardiology</i> , 2007, 50, 514-522.	1.2	138
68	Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease. <i>Thrombosis Research</i> , 2005, 116, 491-497.	0.8	137
69	Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. <i>Lancet</i> , The, 2021, 397, 1470-1483.	6.3	133
70	Variability in Responsiveness to Oral Antiplatelet Therapy. <i>American Journal of Cardiology</i> , 2009, 103, 27A-34A.	0.7	132
71	Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 34, 44-55.	1.0	131
72	Risk of Myocardial Infarction and Angina in Patients With Severe Peripheral Vascular Disease. <i>Circulation</i> , 2002, 105, 800-803.	1.6	130

#	ARTICLE	IF	CITATIONS
73	Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes. <i>International Journal of Cardiology</i> , 2011, 150, 325-331.	0.8	129
74	The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Clopidogrel and Prasugrel. <i>Journal of the American College of Cardiology</i> , 2013, 62, 505-512.	1.2	128
75	Influence of Genetic Polymorphisms on the Effect of High- and Standard-Dose Clopidogrel After Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1928-1937.	1.2	127
76	Antithrombotic Therapy in Patients With Chronic Kidney Disease. <i>Circulation</i> , 2012, 125, 2649-2661.	1.6	127
77	Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PPCI. <i>Journal of the American College of Cardiology</i> , 2019, 74, 83-99.	1.2	126
78	Randomized Trial of Atopaxar in the Treatment of Patients With Coronary Artery Disease. <i>Circulation</i> , 2011, 123, 1854-1863.	1.6	124
79	Ticagrelor With or Without Aspirin After Complex PPCI. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2414-2424.	1.2	122
80	Coronavirus Disease 2019-Associated Thrombosis and Coagulopathy: Review of the Pathophysiological Characteristics and Implications for Antithrombotic Management. <i>Journal of the American Heart Association</i> , 2021, 10, e019650.	1.6	122
81	Antithrombotic Therapy in the Elderly. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1683-1692.	1.2	121
82	Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus. <i>Journal of the American College of Cardiology</i> , 2017, 69, 603-612.	1.2	121
83	Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. <i>Circulation</i> , 2021, 143, 583-596.	1.6	119
84	Influence of Aspirin Resistance on Platelet Function Profiles in Patients on Long-Term Aspirin and Clopidogrel After Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2006, 97, 38-43.	0.7	117
85	Antiplatelet Therapy in Diabetes: Efficacy and Limitations of Current Treatment Strategies and Future Directions. <i>Diabetes Care</i> , 2009, 32, 531-540.	4.3	115
86	Clopidogrel response variability: Current status and future directions. <i>Thrombosis and Haemostasis</i> , 2009, 102, 07-14.	1.8	114
87	Prevalence, Predictors, and Long-Term Prognosis of Premature Discontinuation of Oral Antiplatelet Therapy After Drug Eluting Stent Implantation. <i>American Journal of Cardiology</i> , 2011, 107, 186-194.	0.7	113
88	Meta-Analysis Appraising High Clopidogrel Loading in Patients Undergoing Percutaneous Coronary Intervention—Conflicts of interest: Dr. Angiolillo is a consultant and on the speaker's bureau for Bristol Myers Squibb, New York, New York, and Sanofi-Aventis, Paris, France. Dr. Biondi-Zoccai has consulted for Boston Scientific, Natick, Massachusetts, and Cordis, Miami, Florida, and received lecture fees from Bristol Myers Squibb. Dr. Montalescot has been a consultant for and/or received research grants from Sa. <i>American Journal of Cardiology</i> , 2007, 100, 1199-1206.	0.7	110
89	Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: Design and rationale of the GRAVITAS trial. <i>American Heart Journal</i> , 2009, 157, 818-824.e1.	1.2	110
90	Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. <i>American Heart Journal</i> , 2016, 182, 125-134.	1.2	108

#	ARTICLE	IF	CITATIONS
91	Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1145-1154.	1.2	108
92	Aspirin for Primary Cardiovascular Risk Prevention and Beyond in Diabetes Mellitus. <i>Circulation</i> , 2016, 134, 1579-1594.	1.6	107
93	The Evolution of Antiplatelet Therapy in the Treatment of Acute Coronary Syndromes. <i>Drugs</i> , 2012, 72, 2087-2116.	4.9	106
94	Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. <i>Circulation</i> , 2019, 139, 1661-1670.	1.6	106
95	Recovery of Platelet Function After Discontinuation of Prasugrel or Clopidogrel Maintenance Dosing in Aspirin-Treated Patients With Stable Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2012, 59, 2338-2343.	1.2	104
96	Crushed Prasugrel Tablets in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1994-2004.	1.2	104
97	Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Coronary Stenting. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 522-534.	1.4	103
98	Pharmacology of emerging novel platelet inhibitors. <i>American Heart Journal</i> , 2008, 156, 10S-15S.	1.2	97
99	Platelet function testing and risk of bleeding complications. <i>Thrombosis and Haemostasis</i> , 2010, 103, 1128-1135.	1.8	97
100	Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes. <i>JAMA Cardiology</i> , 2019, 4, 1092.	3.0	97
101	Multisite Investigation of Strategies for the Implementation of <i>CYP2C19</i> Genotype-Guided Antiplatelet Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 664-674.	2.3	94
102	Antiplatelet therapy after percutaneous coronary intervention. <i>EuroIntervention</i> , 2022, 17, e1371-e1396.	1.4	94
103	Coronary stenting versus balloon angioplasty in small vessels. <i>Journal of the American College of Cardiology</i> , 2004, 43, 1964-1972.	1.2	93
104	Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. <i>European Heart Journal</i> , 2020, 41, 3533-3545.	1.0	93
105	Pharmacogenetics in Cardiovascular Antithrombotic Therapy. <i>Journal of the American College of Cardiology</i> , 2009, 54, 1041-1057.	1.2	92
106	Impact of Intraprocedural Stent Thrombosis During Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2014, 63, 619-629.	1.2	92
107	Management of Antiplatelet Therapy in Patients With Coronary Artery Disease Requiring Cardiac and Noncardiac Surgery. <i>Circulation</i> , 2013, 128, 2785-2798.	1.6	91
108	Derivation, Validation, and Prognostic Utility of a Prediction Rule for Nonresponse to Clopidogrel. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 606-617.	1.1	90

#	ARTICLE	IF	CITATIONS
109	Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial. <i>Journal of the American Heart Association</i> , 2015, 4, e002171.	1.6	89
110	PLA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation. <i>Blood Coagulation and Fibrinolysis</i> , 2004, 15, 89-93.	0.5	88
111	Intravascular Ultrasound Findings During Episodes of Drug-Eluting Stent Thrombosis. <i>Journal of the American College of Cardiology</i> , 2007, 50, 2095-2097.	1.2	88
112	Advances in Antiplatelet Therapy: Agents in Clinical Development. <i>American Journal of Cardiology</i> , 2009, 103, 40A-51A.	0.7	88
113	Vascular Effects of Sirolimus-Eluting Versus Bare-Metal Stents in Diabetic Patients. <i>Journal of the American College of Cardiology</i> , 2006, 47, 2172-2179.	1.2	87
114	Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2020, 17, 242-257.	6.1	87
115	Enhanced Response of Blood Monocytes to In Vitro Lipopolysaccharide-Challenge in Patients With Recurrent Unstable Angina. <i>Circulation</i> , 2001, 103, 2236-2241.	1.6	86
116	Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Patients With Stable Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1500-1509.	1.2	85
117	Randomized Comparison of Ticagrelor versus Prasugrel in Patients with Acute Coronary Syndrome and Planned Invasive Strategy—Design and Rationale of the Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 Trial. <i>Journal of Cardiovascular Translational Research</i> , 2014, 7, 91-100.	1.1	84
118	Assessment of Microcirculatory Remodeling With Intracoronary Flow Velocity and Pressure Measurements. <i>Circulation</i> , 2009, 120, 1561-1568.	1.6	83
119	Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	1.4	83
120	Current concepts on coronary revascularization in diabetic patients. <i>European Heart Journal</i> , 2011, 32, 2748-2757.	1.0	82
121	Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. <i>Circulation</i> , 2016, 134, 780-792.	1.6	82
122	Cangrelor: a review on its mechanism of action and clinical development. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 1195-1201.	0.6	81
123	A Randomized, Double-Blind, Active-Controlled Phase 2 Trial to Evaluate a Novel Selective and Reversible Intravenous and Oral P2Y ₁₂ Inhibitor Elinogrel Versus Clopidogrel in Patients Undergoing Nonurgent Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 336-346.	1.4	81
124	Prasugrel 5 mg in the Very Elderly Attenuates Platelet Inhibition But Maintains Noninferiority to Prasugrel 10 mg in Nonelderly Patients. <i>Journal of the American College of Cardiology</i> , 2013, 62, 577-583.	1.2	81
125	Clinical Pharmacology and Cardiovascular Safety of Naproxen. <i>American Journal of Cardiovascular Drugs</i> , 2017, 17, 97-107.	1.0	81
126	A Multidisciplinary Approach on the Perioperative Antithrombotic Management of Patients With Coronary Stents Undergoing Surgery. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 417-434.	1.1	81

#	ARTICLE	IF	CITATIONS
127	Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials. <i>European Heart Journal</i> , 2022, 43, 959-967.	1.0	79
128	Aspirin Desensitization in Patients Undergoing Percutaneous Coronary Interventions With Stent Implantation. <i>American Journal of Cardiology</i> , 2008, 101, 786-789.	0.7	78
129	Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y ₁₂ receptor antagonist. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 151-158.	0.6	76
130	Antithrombotic therapy for patients with STEMI undergoing primary PCI. <i>Nature Reviews Cardiology</i> , 2017, 14, 361-379.	6.1	76
131	Reduction in Platelet Reactivity With Prasugrel 5 mg in Low-Body-Weight Patients Is Noninferior to Prasugrel 10 mg in Higher-Body-Weight Patients. <i>Journal of the American College of Cardiology</i> , 2012, 60, 2032-2040.	1.2	75
132	Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial. <i>European Heart Journal</i> , 2007, 28, 1946-1952.	1.0	73
133	Vorapaxar in Patients With Diabetes Mellitus and Previous Myocardial Infarction. <i>Circulation</i> , 2015, 131, 1047-1053.	1.6	73
134	Functional Effects of High Clopidogrel Maintenance Dosing in Patients With Inadequate Platelet Inhibition on Standard Dose Treatment. <i>American Journal of Cardiology</i> , 2008, 101, 440-445.	0.7	72
135	Reduction in First and Recurrent Cardiovascular Events With Ticagrelor Compared With Clopidogrel in the PLATO Study. <i>Circulation</i> , 2013, 127, 673-680.	1.6	72
136	Overall and Cause-Specific Mortality in Randomized Clinical Trials Comparing Percutaneous Interventions With Coronary Bypass Surgery. <i>JAMA Internal Medicine</i> , 2020, 180, 1638.	2.6	72
137	Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. <i>Thrombosis and Haemostasis</i> , 2008, 99, 161-168.	1.8	71
138	Impact of Escalating Loading Dose Regimens of Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1457-1467.	1.1	71
139	Bleeding avoidance strategies in percutaneous coronary intervention. <i>Nature Reviews Cardiology</i> , 2022, 19, 117-132.	6.1	71
140	Variability of Individual Platelet Reactivity Over Time in Patients Treated With Clopidogrel. <i>Journal of the American College of Cardiology</i> , 2014, 64, 361-368.	1.2	70
141	Impact of race and gender on antithrombotic therapy. <i>Thrombosis and Haemostasis</i> , 2010, 104, 471-484.	1.8	68
142	Management of Antiplatelet and Anticoagulant Therapy in Patients With Atrial Fibrillation in the Setting of Acute Coronary Syndromes or Percutaneous Coronary Interventions. <i>Circulation: Cardiovascular Interventions</i> , 2014, 7, 113-124.	1.4	67
143	Long-Term Outcomes of Patients With Acute Coronary Syndrome and Nonobstructive Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2013, 112, 150-155.	0.7	66
144	Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet Substudy. <i>Journal of the American College of Cardiology</i> , 2020, 75, 578-586.	1.2	66

#	ARTICLE	IF	CITATIONS
145	Antibody Response to Chlamydial Heat Shock Protein 60 Is Strongly Associated With Acute Coronary Syndromes. <i>Circulation</i> , 2003, 107, 3015-3017.	1.6	65
146	Platelet Biology and Response to Antiplatelet Therapy in Women. <i>Journal of the American College of Cardiology</i> , 2012, 59, 891-900.	1.2	65
147	Institutional profile: University of Florida Health Personalized Medicine Program. <i>Pharmacogenomics</i> , 2017, 18, 421-426.	0.6	64
148	Standardized classification and framework for reporting, interpreting, and analysing medication non-adherence in cardiovascular clinical trials: a consensus report from the Non-adherence Academic Research Consortium (NARC). <i>European Heart Journal</i> , 2019, 40, 2070-2085.	1.0	64
149	Timing of Oral P2Y12 Inhibitor Administration in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2450-2459.	1.2	64
150	Short Duration of DAPT Versus De-Escalation After Percutaneous Coronary Intervention for Acute Coronary Syndromes. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 268-277.	1.1	62
151	New Directions in Antiplatelet Therapy. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 433-445.	1.4	61
152	Evolution of Coronary Stent Technology and Implications for Duration of Dual Antiplatelet Therapy. <i>Progress in Cardiovascular Diseases</i> , 2018, 60, 478-490.	1.6	61
153	Variability in Platelet Aggregation Following Sustained Aspirin and Clopidogrel Treatment in Patients With Coronary Heart Disease and Influence of the 807 C/T Polymorphism of the Glycoprotein Ia Gene. <i>American Journal of Cardiology</i> , 2005, 96, 1095-1099.	0.7	60
154	Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2403-2413.	1.2	60
155	Pharmacodynamic Effects of Concomitant Versus Staggered Clopidogrel and Omeprazole Intake. <i>Circulation: Cardiovascular Interventions</i> , 2010, 3, 436-441.	1.4	58
156	Impact of Insulin Receptor Substrate-1 Genotypes on Platelet Reactivity and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2011, 58, 30-39.	1.2	58
157	Pretreatment With Antiplatelet Drugs in Invasively Managed Patients With Coronary Artery Disease in the Contemporary Era. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e002301.	1.4	58
158	Complete versus incomplete revascularization in patients with multivessel disease undergoing percutaneous coronary intervention with drug-eluting stents. <i>Catheterization and Cardiovascular Interventions</i> , 2008, 72, 448-456.	0.7	57
159	Role of genetic testing in patients undergoing percutaneous coronary intervention. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 151-164.	1.3	57
160	Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention. <i>Heart</i> , 2016, 102, 617-625.	1.2	56
161	Use of Antiplatelet Therapy/DAPT for Post-PCI Patients Undergoing Noncardiac Surgery. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1861-1870.	1.2	56
162	Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients With Multivessel Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2018, 71, 489-496.	1.2	56

#	ARTICLE	IF	CITATIONS
163	3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 1870-1883.	1.1	56
164	Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR. <i>European Heart Journal</i> , 2021, 42, 4624-4634.	1.0	54
165	Gene sequence variations of the platelet P2Y12 receptor are associated with coronary artery disease. <i>BMC Medical Genetics</i> , 2007, 8, 59.	2.1	53
166	Aspirin and clopidogrel: efficacy and resistance in diabetes mellitus. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2009, 23, 375-388.	2.2	53
167	P2Y ₁₂ -ADP Receptor Blockade in Chronic Kidney Disease Patients With Acute Coronary Syndromes. <i>Circulation</i> , 2018, 138, 1582-1596.	1.6	53
168	ADP Receptor Antagonism. <i>American Journal of Cardiovascular Drugs</i> , 2007, 7, 423-432.	1.0	52
169	Cangrelor: a review on pharmacology and clinical trial development. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 1279-1291.	0.6	52
170	A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study. <i>European Heart Journal</i> , 2016, 37, 2722-2730.	1.0	52
171	Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes. <i>European Heart Journal</i> , 2020, 41, 3132-3140.	1.0	52
172	Safety and Efficacy of Double Antithrombotic Therapy With Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2020, 9, e017212.	1.6	52
173	Characterization of Plaque Prolapse After Drug-Eluting Stent Implantation in Diabetic Patients. <i>Journal of the American College of Cardiology</i> , 2006, 48, 1139-1145.	1.2	51
174	Clinical impact of in-stent late loss after drug-eluting coronary stent implantation. <i>European Heart Journal</i> , 2007, 28, 1583-1591.	1.0	51
175	A Systematic Review of Outcomes in Patients With Staged Carotid Artery Stenting and Coronary Artery Bypass Graft Surgery. <i>Stroke</i> , 2008, 39, 361-365.	1.0	51
176	Elinogrel: pharmacological principles, preclinical and early phase clinical testing. <i>Future Cardiology</i> , 2010, 6, 445-453.	0.5	51
177	Clopidogrel-Statins Interaction. <i>Journal of the American College of Cardiology</i> , 2007, 50, 296-298.	1.2	50
178	Update on platelet glycoprotein IIb/IIIa inhibitors: recommendations for clinical practice. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2013, 7, 197-213.	1.0	50
179	Platelet reactivity during ticagrelor maintenance therapy: A patient-level data meta-analysis. <i>American Heart Journal</i> , 2014, 168, 530-536.	1.2	50
180	807 C/T Polymorphism of the glycoprotein Ia gene and pharmacogenetic modulation of platelet response to dual antiplatelet treatment. <i>Blood Coagulation and Fibrinolysis</i> , 2004, 15, 427-433.	0.5	49

#	ARTICLE	IF	CITATIONS
181	Current antiplatelet therapies: Benefits and limitations. <i>American Heart Journal</i> , 2008, 156, 3S-9S.	1.2	48
182	Cigarette Smoking Is Associated With a Dose-Response Effect in Clopidogrel-Treated Patients With Diabetes Mellitus and Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 293-300.	1.1	48
183	Impact of Smoking on Long-Term Outcomes in Patients With Atherosclerotic Vascular Disease Treated With Aspirin or Clopidogrel. <i>Journal of the American College of Cardiology</i> , 2014, 63, 769-777.	1.2	47
184	Intravenous antiplatelet therapies (glycoprotein IIb/IIIa receptor inhibitors and cangrelor) in percutaneous coronary intervention: from pharmacology to indications for clinical use. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2019, 13, 175394471989327.	1.0	47
185	Vessel Shrinkage as a Sign of Atherosclerosis Progression in Type 2 Diabetes. <i>Diabetes</i> , 2009, 58, 209-214.	0.3	46
186	Platelet Function Profiles in Patients with Diabetes Mellitus. <i>Journal of Cardiovascular Translational Research</i> , 2013, 6, 329-345.	1.1	46
187	Tailoring duration of DAPT with risk scores. <i>Lancet, The</i> , 2017, 389, 987-989.	6.3	46
188	Antiplatelet Therapy After Implantation of Bioresorbable Vascular Scaffolds. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 425-437.	1.1	46
189	Pharmacodynamic Effects of Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease. <i>Circulation</i> , 2018, 137, 2450-2462.	1.6	46
190	Clinical profile of prasugrel, a novel thienopyridine. <i>American Heart Journal</i> , 2008, 156, 16S-22S.	1.2	45
191	Diabetes and antiplatelet therapy: from bench to bedside. <i>Cardiovascular Diagnosis and Therapy</i> , 2018, 8, 594-609.	0.7	45
192	Stroke After Coronary Artery Bypass Grafting and Percutaneous Coronary Intervention: Incidence, Pathogenesis, and Outcomes. <i>Journal of the American Heart Association</i> , 2019, 8, e013032.	1.6	45
193	Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 677-686.	1.4	45
194	Hypertriglyceridemia and Ischemic Stroke. <i>European Neurology</i> , 2008, 60, 269-278.	0.6	44
195	Age- and Weight-Adapted Dose of Prasugrel Versus Standard Dose of Ticagrelor in Patients With Acute Coronary Syndromes. <i>Annals of Internal Medicine</i> , 2020, 173, 436-444.	2.0	44
196	Prognostic impact of a chronic occlusion in a noninfarct vessel in patients with acute myocardial infarction and multivessel disease undergoing primary percutaneous coronary intervention. <i>Journal of Invasive Cardiology</i> , 2006, 18, 16-9.	0.4	44
197	Antiplatelet therapy in type 2 diabetes mellitus. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2007, 14, 124-131.	1.2	43
198	Clinical overview of promising nonthienopyridine antiplatelet agents. <i>American Heart Journal</i> , 2008, 156, 23S-28S.	1.2	43

#	ARTICLE	IF	CITATIONS
199	Prasugrel: a novel platelet ADP P2Y ₁₂ receptor antagonist. A review on its mechanism of action and clinical development. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 2893-2900.	0.9	43
200	Effect on Platelet Reactivity From a Prasugrel Loading Dose After a Clopidogrel Loading Dose Compared With a Prasugrel Loading Dose Alone. <i>Circulation: Cardiovascular Interventions</i> , 2013, 6, 567-574.	1.4	42
201	Non-cardiac surgery in patients with coronary artery disease: risk evaluation and periprocedural management. <i>Nature Reviews Cardiology</i> , 2021, 18, 37-57.	6.1	42
202	Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI. <i>Journal of the American College of Cardiology</i> , 2016, 67, 603-613.	1.2	41
203	Antithrombotic therapy for acute coronary syndrome: Past, present and future. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1240-1248.	1.8	41
204	Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention. <i>Journal of Translational Medicine</i> , 2018, 16, 92.	1.8	41
205	Rationale and design of the Virginia Commonwealth University Anakinra Remodeling Trial (VCU CART3): A randomized, placebo-controlled, double-blind, multicenter study. <i>Clinical Cardiology</i> , 2018, 41, 1004-1008.	0.7	41
206	Ticagrelor or Prasugrel in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2436-2446.	1.2	41
207	Predictive accuracy of CHA ₂ DS ₂ -VASc and HAS-BLED scores in patients without atrial fibrillation undergoing percutaneous coronary intervention and discharged on dual antiplatelet therapy. <i>International Journal of Cardiology</i> , 2015, 199, 319-325.	0.8	39
208	Dual antiplatelet therapy guided by platelet function testing. <i>Lancet, The</i> , 2017, 390, 1718-1720.	6.3	39
209	Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI. <i>Journal of the American College of Cardiology</i> , 2021, 78, 2060-2072.	1.2	39
210	Impact of Gene Polymorphisms, Platelet Reactivity, and the SYNTAX Score on 1-Year Clinical Outcomes in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 1117-1127.	1.1	38
211	Inhibitory mechanisms of very low-dose rivaroxaban in non-ST-elevation myocardial infarction. <i>Blood Advances</i> , 2018, 2, 715-730.	2.5	38
212	Impact of P2Y ₁₂ Inhibitory Effects Induced by Clopidogrel on Platelet Procoagulant Activity in Type 2 Diabetes Mellitus Patients. <i>Thrombosis Research</i> , 2009, 124, 318-322.	0.8	37
213	Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy. <i>Thrombosis and Haemostasis</i> , 2011, 106, 253-262.	1.8	37
214	Operator Radiation Exposure and Physical Discomfort During a Right Versus Left Radial Approach for Coronary Interventions. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 810-816.	1.1	37
215	Antiplatelet drug response variability and the role of platelet function testing: A practical guide for interventional cardiologists. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 73, 1-14.	0.7	36
216	Platelet Adenosine Diphosphate P2Y ₁₂ Receptor Antagonism: Benefits and Limitations of Current Treatment Strategies and Future Directions. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2010, 63, 60-76.	0.4	36

#	ARTICLE	IF	CITATIONS
217	Haemostatic profiles assessed by thromboelastography in patients with end-stage renal disease. <i>Thrombosis and Haemostasis</i> , 2011, 106, 67-74.	1.8	36
218	Antiplatelet and Anticoagulant Therapy for Atherothrombotic Disease: The Role of Current and Emerging Agents. <i>American Journal of Cardiovascular Drugs</i> , 2013, 13, 233-250.	1.0	36
219	Pharmacodynamic Evaluation of Pantoprazole Therapy on Clopidogrel Effects. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 273-279.	1.4	35
220	Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1089-1098.	1.1	35
221	Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1468-1483.	1.2	35
222	Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease. <i>Circulation</i> , 2021, 144, 1323-1343.	1.6	35
223	Evaluation of cardiac magnetic resonance imaging parameters to detect anatomically and hemodynamically significant coronary artery disease. <i>American Heart Journal</i> , 2007, 154, 298-305.	1.2	34
224	Identifying the "Optimal" Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Revascularization. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 1279-1285.	1.1	34
225	Functional profile of the platelet P2Y12 receptor signalling pathway in patients with type 2 diabetes mellitus and coronary artery disease. <i>Thrombosis and Haemostasis</i> , 2011, 105, 730-732.	1.8	34
226	Antiplatelet therapy: thrombin receptor antagonists. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 658-671.	1.1	34
227	Successful pregnancy and delivery on prasugrel treatment: considerations for the use of dual antiplatelet therapy during pregnancy in clinical practice. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 36, 348-351.	1.0	34
228	Platelet Function Testing in Contemporary Clinical and Interventional Practice. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2014, 16, 300.	0.4	34
229	Impact of opioids on P2Y12 receptor inhibition in patients with ST-elevation myocardial infarction who are pre-treated with crushed ticagrelor: Opioids and crushed Ticagrelor In Myocardial infarction Evaluation (ON-TIME 3) trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 4-12.	1.4	34
230	The Problem of Persistent Platelet Activation in Acute Coronary Syndromes and Following Percutaneous Coronary Intervention. <i>Clinical Cardiology</i> , 2008, 31, 117-120.	0.7	33
231	Pharmacokinetic and Pharmacodynamic Effects of Elinogrel. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 347-356.	1.4	33
232	Impact of Diabetes Mellitus and Chronic Kidney Disease on Cardiovascular Outcomes and Platelet P2Y ₁₂ Receptor Antagonist Effects in Patients With Acute Coronary Syndromes: Insights From the PLATO Trial. <i>Journal of the American Heart Association</i> , 2019, 8, e011139.	1.6	33
233	Fractional Flow Reserve-Based Coronary Artery Bypass Surgery. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1086-1096.	1.1	32
234	Cilostazol: a Review of Basic Mechanisms and Clinical Uses. <i>Cardiovascular Drugs and Therapy</i> , 2022, 36, 777-792.	1.3	32

#	ARTICLE	IF	CITATIONS
235	LDL-cholesterol predicts negative coronary artery remodelling in diabetic patients: an intravascular ultrasound study. <i>European Heart Journal</i> , 2005, 26, 2307-2312.	1.0	31
236	Platelet function testing and cardiovascular outcomes: Steps forward in identifying the best predictive measure. <i>Thrombosis and Haemostasis</i> , 2007, 98, 707-709.	1.8	31
237	Effect of a Contrast Modulation System on Contrast Media Use and the Rate of Acute Kidney Injury After Coronary Angiography. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1601-1610.	1.1	31
238	Cangrelor: Clinical Data, Contemporary Use, and Future Perspectives. <i>Journal of the American Heart Association</i> , 2021, 10, e022125.	1.6	31
239	Antithrombotic Therapy After Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 1688-1703.	1.1	31
240	Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	30
241	P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention. <i>Nature Reviews Cardiology</i> , 2022, 19, 829-844.	6.1	30
242	Platelet function profiles in the elderly: Results of a pharmacodynamic study in patients on clopidogrel therapy and effects of switching to prasugrel 5 mg in patients with high platelet reactivity. <i>Thrombosis and Haemostasis</i> , 2011, 106, 1149-1157.	1.8	29
243	Three-Dimensional Echocardiography for Transcatheter Aortic Valve Replacement Sizing: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2019, 8, e013463.	1.6	29
244	Antithrombotic therapy in diabetes: which, when, and for how long?. <i>European Heart Journal</i> , 2021, 42, 2235-2259.	1.0	29
245	Platelet Function and Genetic Testing. <i>Journal of the American College of Cardiology</i> , 2013, 62, S21-S31.	1.2	28
246	Pharmacodynamic Effects of Cangrelor on Platelet P2Y12 Receptor-Mediated Signaling in Prasugrel-Treated Patients. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 426-434.	1.1	28
247	Ticagrelor or Prasugrel for Platelet Inhibition in Acute Coronary Syndrome Patients. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2569-2571.	1.2	28
248	Long-Term Safety and Efficacy of Durable Polymer Cobalt-Chromium Everolimus-Eluting Stents in Patients at High Bleeding Risk. <i>Circulation</i> , 2020, 141, 891-901.	1.6	28
249	Heterogeneity of atherosclerotic plaque characteristics in human coronary artery disease: A three-dimensional intravascular ultrasound study. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 70, 349-356.	0.7	27
250	Effects of intensive glucose control on platelet reactivity in patients with acute coronary syndromes. Results of the CHIPS Study ("Control de Hiperglucemia y Actividad Plaquetaria en Pacientes) <i>Tj ETQq0 0.0 rgBT / Overlock 10</i>		
251	The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease. <i>Thrombosis and Haemostasis</i> , 2014, 112, 589-597.	1.8	27
252	Ticagrelor or Prasugrel in Patients With Acute Coronary Syndromes and Diabetes Mellitus. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2238-2247.	1.1	27

#	ARTICLE	IF	CITATIONS
253	Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 444-456.	1.1	27
254	Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendations. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 963-978.	1.3	27
255	Sex Differences Among Patients With High Risk Receiving Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention. <i>JAMA Cardiology</i> , 2021, 6, 1032.	3.0	27
256	Relationship between diabetes, platelet reactivity, and the SYNTAX score to one-year clinical outcome in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention. <i>EuroIntervention</i> , 2016, 12, 312-318.	1.4	27
257	“Candy wrapper” effect after drug-eluting stent implantation: DÅ©jÃ vu or stumbling over the same stone again?. <i>Catheterization and Cardiovascular Interventions</i> , 2004, 61, 387-391.	0.7	26
258	Lack of association between gene sequence variations of platelet membrane receptors and aspirin responsiveness detected by the PFA-100 system in patients with coronary artery disease. <i>Platelets</i> , 2006, 17, 586-590.	1.1	26
259	Assessing the Current Role of Platelet Function Testing. <i>Clinical Cardiology</i> , 2008, 31, 110-116.	0.7	26
260	Impact of bridging with perioperative low-molecular-weight heparin on cardiac and bleeding outcomes of stented patients undergoing non-cardiac surgery. <i>Thrombosis and Haemostasis</i> , 2015, 114, 423-431.	1.8	26
261	Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trials. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 40, 317-322.	1.0	26
262	Effects of Methylnaltrexone on Ticagrelor-Induced Antiplatelet Effects inÂCoronary Artery Disease Patients Treated With Morphine. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1538-1549.	1.1	26
263	Pharmacokinetic/pharmacodynamic assessment of a novel, pharmaceutical lipidâ€“aspirin complex: results of a randomized, crossover, bioequivalence study. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 554-562.	1.0	26
264	De-escalation from ticagrelor to clopidogrel in acute coronary syndrome patients: a systematic review and meta-analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 1-10.	1.0	26
265	Effect of Prehospital Crushed Prasugrel Tablets in Patients With ST-Segmentâ€“Elevation Myocardial Infarction Planned for Primary Percutaneous Coronary Intervention. <i>Circulation</i> , 2020, 142, 2316-2328.	1.6	26
266	Antithrombotic Therapy for Atherosclerotic Cardiovascular Disease Risk Mitigation in Patients With Coronary Artery Disease and Diabetes Mellitus. <i>Circulation</i> , 2020, 142, 2172-2188.	1.6	26
267	Ticagrelor or Prasugrel in Patients With ST-Segmentâ€“Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. <i>Circulation</i> , 2020, 142, 2329-2337.	1.6	26
268	Intracoronary Brachytherapy After Stenting De Novo Lesions in Diabetic Patients. <i>Journal of the American College of Cardiology</i> , 2004, 44, 520-527.	1.2	25
269	Intravascular Ultrasound Characterization of the “Black Hole” Phenomenon After Drug-Eluting Stent Implantation. <i>American Journal of Cardiology</i> , 2006, 97, 203-206.	0.7	25
270	Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R). Rationale for the Study and Protocol Design. <i>Cardiovascular Drugs and Therapy</i> , 2008, 22, 313-320.	1.3	25

#	ARTICLE	IF	CITATIONS
271	Different Apparent Prognostic Value of hsCRP in Type 2 Diabetic and Nondiabetic Patients with Acute Coronary Syndromes. <i>Clinical Chemistry</i> , 2009, 55, 365-368.	1.5	25
272	The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction. <i>American Heart Journal</i> , 2019, 208, 81-90.	1.2	25
273	Selatogrel, a novel P2Y ₁₂ inhibitor: a review of the pharmacology and clinical development. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 537-546.	1.9	25
274	Impact of the <i>CYP2C19*17</i> Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 705-715.	2.3	25
275	Investigations on 5-HT ₄ Receptor Expression and Effects of Tegaserod on Human Platelet Aggregation In Vitro. <i>American Journal of Therapeutics</i> , 2010, 17, 543-552.	0.5	24
276	Update on the clinical development of cangrelor. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 1069-1077.	0.6	24
277	Platelet P2Y ₁₂ Receptor Inhibition. <i>American Journal of Cardiovascular Drugs</i> , 2010, 10, 217-226.	1.0	24
278	Effects of cangrelor in coronary artery disease patients with and without diabetes mellitus: an in vitro pharmacodynamic investigation. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 35, 155-164.	1.0	24
279	Cigarette Smoking and Antiplatelet Effects of Aspirin Monotherapy Versus Clopidogrel Monotherapy in Patients with Atherosclerotic Disease: Results of a Prospective Pharmacodynamic Study. <i>Journal of Cardiovascular Translational Research</i> , 2014, 7, 53-63.	1.1	24
280	Antithrombotic therapy for secondary prevention of atherothrombotic events in cerebrovascular disease. <i>Nature Reviews Cardiology</i> , 2016, 13, 609-622.	6.1	24
281	Systematic Evaluation of the Robustness of the Evidence Supporting Current Guidelines on Myocardial Revascularization Using the Fragility Index. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e006017.	0.9	24
282	<i>CYP2C19</i> Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings. <i>Journal of the American Heart Association</i> , 2022, 11, e024159.	1.6	24
283	Head-to-head comparison between sirolimus-eluting and paclitaxel-eluting stents in patients with complex coronary artery disease: An intravascular ultrasound study. <i>Catheterization and Cardiovascular Interventions</i> , 2006, 67, 846-851.	0.7	23
284	High-Dose Atorvastatin on the Pharmacodynamic Effects of Double-Dose Clopidogrel in Patients Undergoing Percutaneous Coronary Interventions. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 169-179.	1.1	23
285	Effects of dabigatran on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. <i>Thrombosis and Haemostasis</i> , 2016, 115, 622-631.	1.8	23
286	Bleeding after antiplatelet therapy for the treatment of acute coronary syndromes: a review of the evidence and evolving paradigms. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 1171-1189.	1.0	23
287	Lipid Management in Patients Presenting With Acute Coronary Syndromes: A Review. <i>Journal of the American Heart Association</i> , 2020, 9, e018897.	1.6	23
288	Dual Pathway Inhibition for Vascular Protection in Patients with Atherosclerotic Disease: Rationale and Review of the Evidence. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1147-1158.	1.8	23

#	ARTICLE	IF	CITATIONS
289	Is a 300 mg clopidogrel loading dose sufficient to inhibit platelet function early after coronary stenting? A platelet function profile study. <i>Journal of Invasive Cardiology</i> , 2004, 16, 325-9.	0.4	23
290	Long-term clinical outcomes after drug-eluting stent implantation in unprotected left main coronary artery disease. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 73, 291-298.	0.7	22
291	Optimizing Platelet Inhibition in Clopidogrel Poor Metabolizers. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 411-414.	1.1	22
292	The influence of body size on the pharmacodynamic and pharmacokinetic response to clopidogrel and prasugrel: A retrospective analysis of the FEATHER study. <i>Thrombosis Research</i> , 2014, 134, 552-557.	0.8	22
293	Novel Antiplatelet Agents: The Current State and What Is Coming Down the Pike. <i>Progress in Cardiovascular Diseases</i> , 2015, 58, 267-277.	1.6	22
294	Antithrombotic Management of Elderly Patients With Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 723-738.	1.1	22
295	Guided and unguided de-escalation from potent P2Y12 inhibitors among patients with acute coronary syndrome: a meta-analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 492-502.	1.4	22
296	ABCD-GENE Score and Clinical Outcomes Following Percutaneous Coronary Intervention: Insights from the TAILOR-PCI Trial. <i>Journal of the American Heart Association</i> , 2022, 11, e024156.	1.6	22
297	Use of Impella Recover LP 2.5 in elective high risk percutaneous coronary intervention. <i>International Journal of Cardiology</i> , 2010, 145, 235-237.	0.8	21
298	The role of oral anticoagulant therapy in patients with acute coronary syndrome. <i>Therapeutic Advances in Hematology</i> , 2017, 8, 353-366.	1.1	21
299	Antiplatelet therapy and outcome in patients undergoing surgery following coronary stenting: Results of the surgery after stenting registry. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, E13-E25.	0.7	21
300	Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes status. <i>Thrombosis and Haemostasis</i> , 2017, 117, 940-947.	1.8	21
301	Effects of Edoxaban on the Cellular and Protein Phase of Coagulation in Patients with Coronary Artery Disease on Dual Antiplatelet Therapy with Aspirin and Clopidogrel: Results of the EDOX-APT Study. <i>Thrombosis and Haemostasis</i> , 2020, 120, 083-093.	1.8	21
302	Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent. <i>American Heart Journal</i> , 2021, 231, 147-156.	1.2	21
303	Antithrombotic therapy after percutaneous coronary intervention of bifurcation lesions. <i>EuroIntervention</i> , 2021, 17, 59-66.	1.4	21
304	Role of platelet function and genetic testing in patients undergoing percutaneous coronary intervention. <i>Trends in Cardiovascular Medicine</i> , 2023, 33, 133-138.	2.3	21
305	Mechanism of action and clinical development of platelet thrombin receptor antagonists. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 1191-1200.	0.6	20
306	Antithrombotic Therapy for Prevention of Cerebral Thromboembolic Events After Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1366-1369.	1.1	20

#	ARTICLE	IF	CITATIONS
307	Gender differences on benefits and risks associated with oral antithrombotic medications for coronary artery disease. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 1041-1052.	1.0	20
308	Aspirin for the primary prevention of cardiovascular disease: latest evidence. <i>Expert Review of Cardiovascular Therapy</i> , 2019, 17, 633-643.	0.6	20
309	Challenges and Perspectives of Antiplatelet Therapy in Patients with Diabetes Mellitus and Coronary Artery Disease. <i>Current Pharmaceutical Design</i> , 2012, 18, 5273-5293.	0.9	19
310	Switching antiplatelet regimens: Alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: A review of the literature and practical considerations for the interventional cardiologist. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 81, 232-242.	0.7	19
311	Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: Insights from the switching anti-platelet (SWAP) study. <i>Thrombosis and Haemostasis</i> , 2013, 109, 347-355.	1.8	19
312	Clopidogrel pretreatment in primary percutaneous coronary intervention: Prevalence of high on-treatment platelet reactivity and impact on preprocedural patency of the infarct-related artery. <i>Thrombosis and Haemostasis</i> , 2013, 110, 110-117.	1.8	19
313	Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. <i>Thrombosis and Haemostasis</i> , 2016, 116, 69-77.	1.8	19
314	Assessment of potential relationship between wall shear stress and arterial wall response after bare metal stent and sirolimus-eluting stent implantation in patients with diabetes mellitus. <i>International Journal of Cardiovascular Imaging</i> , 2008, 24, 357-364.	0.7	18
315	Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: Impact of high on-treatment platelet reactivity and diabetes mellitus status. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 81, 42-49.	0.7	18
316	Impact of Mild Hypothermia on Platelet Responsiveness to Aspirin and Clopidogrel: an In Vitro Pharmacodynamic Investigation. <i>Journal of Cardiovascular Translational Research</i> , 2014, 7, 39-46.	1.1	18
317	Ticagrelor Versus Clopidogrel in Black Patients With Stable Coronary Artery Disease. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e002232.	1.4	18
318	Influence of smoking on the antiplatelet effect of clopidogrel differs according to clopidogrel dose: Insights from the GRAVITAS trial. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 190-198.	0.7	18
319	Platelet-related biomarkers and their response to inhibition with aspirin and p2y12-receptor antagonists in patients with acute coronary syndrome. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 44, 145-153.	1.0	18
320	Cardiorenal Safety of OTC Analgesics. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2018, 23, 103-118.	1.0	18
321	High on-treatment platelet reactivity and outcome in elderly with non ST-segment elevation acute coronary syndrome - Insight from the GEPRESS study. <i>International Journal of Cardiology</i> , 2018, 259, 20-25.	0.8	18
322	CSL112, a reconstituted, infusible, plasma-derived apolipoprotein A-I: safety and tolerability profiles and implications for management in patients with myocardial infarction. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 997-1005.	1.9	18
323	Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-Function Genotypes. <i>JACC Basic To Translational Science</i> , 2020, 5, 419-428.	1.9	18
324	Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y ₁₂ Receptor Inhibitors With and Without Aspirin: Results of the VORA-PRATIC Study. <i>Journal of the American Heart Association</i> , 2020, 9, e015865.	1.6	18

#	ARTICLE	IF	CITATIONS
325	Safety and efficacy of P2Y ₁₂ inhibitor monotherapy in patients undergoing percutaneous coronary interventions. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 9-21.	1.0	18
326	Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD. <i>European Heart Journal</i> , 2021, 42, 4683-4693.	1.0	18
327	Relocation of minimal luminal diameter after bare metal and drug-eluting stent implantation: Incidence and impact on angiographic late loss. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 69, 181-188.	0.7	17
328	Impact of Pentoxifylline on Platelet Function Profiles in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and Clopidogrel. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 905-912.	1.1	17
329	Impact of a Fixed-Dose Combination of Naproxen and Esomeprazole Magnesium on Serum Thromboxane B ₂ Inhibition by Low-Dose Aspirin Over 5 Days in Healthy Adults: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Noninferiority Trial. <i>Clinical Therapeutics</i> , 2011, 33, 1883-1893.	1.1	17
330	Advances in platelet function testing assessing bleeding complications in patients with coronary artery disease. <i>Platelets</i> , 2012, 23, 537-551.	1.1	17
331	Targeting P-Selectin During Coronary Interventions. <i>Journal of the American College of Cardiology</i> , 2013, 61, 2056-2059.	1.2	17
332	Impact of concomitant low-dose aspirin on the safety and tolerability of naproxen and esomeprazole magnesium delayed-release tablets in patients requiring chronic nonsteroidal anti-inflammatory drug therapy: an analysis from 5 Phase III studies. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 38, 11-23.	1.0	17
333	Platelet thrombin receptor antagonism with vorapaxar: pharmacology and clinical trial development. <i>Future Cardiology</i> , 2015, 11, 547-564.	0.5	17
334	Role for Thrombin Receptor Antagonism With Vorapaxar in Secondary Prevention of Atherothrombotic Events: From Bench to Bedside. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2018, 23, 23-37.	1.0	17
335	The quest for safer antithrombotic treatment regimens in patients with coronary artery disease: new strategies and paradigm shifts. <i>Expert Review of Hematology</i> , 2018, 11, 5-12.	1.0	17
336	Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2021, 10, e017008.	1.6	17
337	Variable histological and ultrasonic characteristics of restenosis after drug-eluting stents. <i>International Journal of Cardiology</i> , 2008, 130, 444-448.	0.8	16
338	Pharmacodynamic Effects of Prasugrel Dosing Regimens in Patients on Maintenance Prasugrel Therapy. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1681-1687.	1.2	16
339	Atopaxar and its effects on markers of platelet activation and inflammation: results from the LANCELOT CAD program. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 34, 36-43.	1.0	16
340	Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patients. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 38, 127-36.	1.0	16
341	Cluster-Randomized Clinical Trial Examining the Impact of Platelet Function Testing on Practice. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e001712.	1.4	16
342	Antithrombotic Therapy for Secondary Prevention in Patients With Diabetes Mellitus and Coronary Artery Disease. <i>Circulation Journal</i> , 2016, 80, 791-801.	0.7	16

#	ARTICLE	IF	CITATIONS
343	Emergency Consent: Patientsâ€™ and Surrogatesâ€™ Perspectives on Consent for Clinical Trials in Acute Stroke and Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2019, 8, e010905.	1.6	16
344	Pharmacokineticâ€“pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 413-421.	1.1	16
345	Aspirin for Primary Prevention of Cardiovascular Disease in the 21st Century: A Review of the Evidence. <i>American Journal of Cardiology</i> , 2021, 144, S15-S22.	0.7	16
346	Bridging Antiplatelet Therapy After Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1550-1563.	1.2	16
347	Role of thromboelastography and rapid thromboelastography to assess the pharmacodynamic effects of vitamin K antagonists. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 40, 118-125.	1.0	15
348	Pooled comparison of regadenoson versus adenosine for measuring fractional flow reserve and coronary flow in the catheterization laboratory. <i>Cardiovascular Revascularization Medicine</i> , 2015, 16, 266-271.	0.3	15
349	Impact of residual platelet reactivity on reperfusion in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2016, 5, 475-486.	0.4	15
350	Triple Antithrombotic Therapy at the Intercept Between Threats and Opportunities. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1086-1088.	1.1	15
351	Cigarette smoking reduces platelet reactivity independently of clopidogrel treatment in patients with non-ST elevation acute coronary syndromes. <i>Platelets</i> , 2018, 29, 309-311.	1.1	15
352	Effects of D-allulose on glucose tolerance and insulin response to a standard oral sucrose load: results of a prospective, randomized, crossover study. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e001939.	1.2	15
353	Updated meta-analysis of randomized controlled trials on the safety and efficacy of different prophylactic anticoagulation dosing regimens in non-critically ill hospitalized patients with COVID-19. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, E15-E17.	1.4	15
354	Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants. <i>JAMA Cardiology</i> , 2022, 7, 747.	3.0	15
355	Prasugrel for the treatment of coronary thrombosis: a review of pharmacological properties, indications for use and future development. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 119-133.	1.9	14
356	Impact of renal function on clopidogrel-induced antiplatelet effects in coronary artery disease patients without diabetes mellitus. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 36, 14-17.	1.0	14
357	Canakinumab for secondary prevention of atherosclerotic disease. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 215-220.	1.4	14
358	Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial. <i>Cardiovascular Diabetology</i> , 2020, 19, 179.	2.7	14
359	Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial. <i>Clinical Research in Cardiology</i> , 2020, 109, 930-943.	1.5	14
360	Pharmacokinetic and Pharmacodynamic Profile of a Novel Phospholipid Aspirin Formulation. <i>Clinical Pharmacokinetics</i> , 2022, 61, 465-479.	1.6	14

#	ARTICLE	IF	CITATIONS
361	Antiplatelet drug therapy: role of pharmacodynamic and genetic testing. <i>Future Cardiology</i> , 2011, 7, 381-402.	0.5	13
362	Can resistance to aspirin be reversed after an additional dose?. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 32, 356-361.	1.0	13
363	Effects of pioglitazone on platelet P2Y12-mediated signalling in clopidogrel-treated patients with type 2 diabetes mellitus. <i>Thrombosis and Haemostasis</i> , 2012, 108, 930-936.	1.8	13
364	Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar. <i>Vascular Health and Risk Management</i> , 2014, 10, 177.	1.0	13
365	A randomised trial of the pharmacodynamic and pharmacokinetic effects of ticagrelor compared with clopidogrel in Hispanic patients with stable coronary artery disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 39, 8-14.	1.0	13
366	Percutaneous coronary intervention and atrial fibrillation: the triple therapy dilemma. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 39, 203-208.	1.0	13
367	Reviewing the controversy surrounding pre-treatment with P2Y12inhibitors in acute coronary syndrome patients. <i>Expert Review of Cardiovascular Therapy</i> , 2016, 14, 811-820.	0.6	13
368	Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e005635.	1.4	13
369	Impact of Multidrug Resistance Protein-4 Inhibitors on Modulating Platelet Function and High on-Aspirin Treatment Platelet Reactivity. <i>Thrombosis and Haemostasis</i> , 2018, 118, 490-501.	1.8	13
370	Tailoring P2Y ₁₂ Inhibiting Therapy in Elderly Patients With Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. <i>Journal of the American Heart Association</i> , 2019, 8, e014000.	1.6	13
371	Efficacy and safety of dual-pathway inhibition in patients with cardiovascular disease: a meta-analysis of 49 802 patients from 7 randomized trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 519-528.	1.4	13
372	Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCI. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 1434-1446.	1.1	13
373	Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 361-369.	0.6	12
374	Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways. <i>Thrombosis and Haemostasis</i> , 2013, 110, 1223-1231.	1.8	12
375	Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease. <i>Thrombosis and Haemostasis</i> , 2014, 111, 258-265.	1.8	12
376	Platelet inhibition with ticagrelor versus clopidogrel in Hispanic patients with stable coronary artery disease with or without diabetes mellitus. <i>Cardiovascular Revascularization Medicine</i> , 2015, 16, 450-454.	0.3	12
377	A Safety Evaluation of Cangrelor in Patients Undergoing PCI. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 275-285.	1.0	12
378	Aspirin for primary prevention of cardiovascular disease. <i>Lancet, The</i> , 2018, 392, 988-990.	6.3	12

#	ARTICLE	IF	CITATIONS
379	Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus. <i>JACC Basic To Translational Science</i> , 2019, 4, 763-775.	1.9	12
380	COMPARison of pre-hospital CRUSHed vs. uncrushed Prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary interventions: Rationale and design of the COMPARE CRUSH trial. <i>American Heart Journal</i> , 2020, 224, 10-16.	1.2	12
381	Sex-Related Differences in Patients at High Bleeding Risk Undergoing Percutaneous Coronary Intervention: A Patient-Level Pooled Analysis From 4 Postapproval Studies. <i>Journal of the American Heart Association</i> , 2020, 9, e014611.	1.6	12
382	Antiplatelet Therapy with Cangrelor in Patients Undergoing Surgery after Coronary Stent Implantation: A Real-World Bridging Protocol Experience. <i>TH Open</i> , 2020, 04, e437-e445.	0.7	12
383	Sirolimus-eluting stents for treatment of complex bypass graft disease: insights from the SECURE registry. <i>Journal of Invasive Cardiology</i> , 2005, 17, 396-8.	0.4	12
384	Imaging of atherosclerotic plaque. <i>International Journal of Cardiovascular Imaging</i> , 2004, 20, 553-559.	0.7	11
385	Influence of the CD14 C260T Promoter Polymorphism on C-Reactive Protein Levels in Patients With Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2006, 98, 1182-1184.	0.7	11
386	Diabetes mellitus: a prothrombotic state. Implications for outcomes after coronary revascularization. <i>Vascular Health and Risk Management</i> , 2009, 5, 101.	1.0	11
387	Clopidogrel plus PPIs—a dangerous combination?. <i>Nature Reviews Cardiology</i> , 2009, 6, 392-394.	6.1	11
388	Tackling the thrombotic burden in patients with acute coronary syndrome and diabetes mellitus. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 697-710.	0.6	11
389	Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 80, 395-405.	0.7	11
390	Influence of HbA1c levels on platelet function profiles associated with tight glycemic control in patients presenting with hyperglycemia and an acute coronary syndrome. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 35, 165-174.	1.0	11
391	Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vitro pilot investigation. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 37, 131-138.	1.0	11
392	Efecto del tratamiento optimizado con insulina en la reactividad plaquetaria tras el alta de pacientes hiperglicémicos con síndrome coronario agudo. <i>Revista Espanola De Cardiologia</i> , 2014, 67, 22-27.	0.6	11
393	Defining the Link Between Chronic Kidney Disease, High Platelet Reactivity, and Clinical Outcomes in Clopidogrel-Treated Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e002760.	1.4	11
394	Dual antiplatelet therapy after coronary stenting. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1775-1787.	0.9	11
395	Pre-Treatment With Oral P2Y12 Inhibitors in Acute Coronary Syndromes Without ST-Segment Elevation. <i>Journal of the American College of Cardiology</i> , 2019, 73, 915-918.	1.2	11
396	Tailoring Antiplatelet Therapy in Patients Undergoing Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 33-37.	1.1	11

#	ARTICLE	IF	CITATIONS
397	Bioavailability of aspirin in fasted and fed states of a novel pharmaceutical lipid aspirin complex formulation. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 49, 337-343.	1.0	11
398	Ticagrelor or Prasugrel for Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention. <i>JAMA Cardiology</i> , 2021, 6, 1121.	3.0	11
399	Rationale and design of the BA-SCAD (Beta-blockers and Antiplatelet agents in patients with) Tj ETQq1 1 0.784314 rgBT /Overlock 10 (English Ed), 2022, 75, 515-522.	0.4	11
400	Quantitative contrast enhanced magnetic resonance imaging for the evaluation of peripheral arterial disease: a comparative study versus standard digital angiography. <i>International Journal of Cardiovascular Imaging</i> , 2007, 23, 225-232.	0.7	10
401	Inhibiting PAR-1 in the prevention and treatment of atherothrombotic events. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 1557-1567.	1.9	10
402	Drug-drug interactions between clopidogrel and novel cardiovascular drugs. <i>European Journal of Pharmacology</i> , 2015, 765, 332-336.	1.7	10
403	Switching P2Y12 Receptor Inhibiting Therapies. <i>Interventional Cardiology Clinics</i> , 2017, 6, 67-89.	0.2	10
404	Dual antithrombotic therapy for atrial fibrillation and PCI. <i>Lancet, The</i> , 2019, 394, 1300-1302.	6.3	10
405	Pharmacodynamic and Pharmacokinetic Effects of a Low Maintenance Dose Ticagrelor Regimen Versus Standard Dose Clopidogrel in Diabetes Mellitus Patients Without Previous Major Cardiovascular Events Undergoing Elective Percutaneous Coronary Intervention. <i>Circulation</i> , 2020, 142, 1500-1502.	1.6	10
406	Bridging the gap: Current and future insights for improving suboptimal platelet inhibition in STEMI. <i>International Journal of Cardiology</i> , 2021, 328, 40-45.	0.8	10
407	Use of the VerifyNow point of care assay to assess the pharmacodynamic effects of loading and maintenance dose regimens of prasugrel and ticagrelor. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 741-747.	1.0	10
408	Canakinumab for secondary prevention of coronary artery disease. <i>Future Cardiology</i> , 2021, 17, 427-442.	0.5	10
409	Platelet function testing and cardiovascular outcomes: steps forward in identifying the best predictive measure. <i>Thrombosis and Haemostasis</i> , 2007, 98, 707-9.	1.8	10
410	Unraveling Myths of Platelet Function and Genetic Testing. <i>Journal of the American College of Cardiology</i> , 2011, 57, 2484-2486.	1.2	9
411	Applying Platelet Function Testing in Clinical Practice. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 1260.	3.8	9
412	Impacto del tratamiento adyuvante con cilostazol comparado con dosis altas de mantenimiento de clopidogrel en pacientes con diabetes mellitus y respuesta subóptima. <i>Revista Espanola De Cardiologia</i> , 2012, 65, 105-106.	0.6	9
413	Refining the Role of Antiplatelet Therapy in Medically Managed Patients With Acute Coronary Syndrome. <i>American Journal of Cardiology</i> , 2013, 111, 439-444.	0.7	9
414	Impact of Prasugrel Reload Dosing Regimens on High On-Treatment Platelet Reactivity Rates in Patients on Maintenance Prasugrel Therapy. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 182-184.	1.1	9

#	ARTICLE	IF	CITATIONS
415	Effects of statin therapy on platelet reactivity after percutaneous coronary revascularization in patients with acute coronary syndrome. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 44, 355-361.	1.0	9
416	The Conundrum Surrounding Racial Differences on Ischaemic and Bleeding Risk with Dual Anti-Platelet Therapy. <i>Thrombosis and Haemostasis</i> , 2019, 119, 009-013.	1.8	9
417	Clinical Utility of Pharmacogene Panel-Based Testing in Patients Undergoing Percutaneous Coronary Intervention. <i>Clinical and Translational Science</i> , 2020, 13, 473-481.	1.5	9
418	Evaluating the extent of reusability of CYP2C19 genotype data among patients genotyped for antiplatelet therapy selection. <i>Genetics in Medicine</i> , 2020, 22, 1898-1902.	1.1	9
419	Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome in Relation to Estimated Glomerular Filtration Rate. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 1857-1866.	1.1	9
420	Tackling the diabetic platelet: is high clopidogrel dosing the answer?. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 2563-2565.	1.9	8
421	Angiographic and 3D intravascular ultrasound assessment of overlapping bare metal stent and three different formulations of drug-eluting stents in patients with diabetes mellitus. <i>International Journal of Cardiovascular Imaging</i> , 2008, 24, 125-132.	0.7	8
422	Review article: Antithrombotic therapy in patients with diabetes mellitus and coronary artery disease. <i>Diabetes and Vascular Disease Research</i> , 2010, 7, 274-288.	0.9	8
423	Impact of Gastric Acid-Suppressing Therapies on Platelet Reactivity in Patients With Coronary Artery Disease Treated With Clopidogrel. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1396-1398.	1.2	8
424	Switching From Prasugrel to Clopidogrel. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 166-168.	1.1	8
425	Perspectives on the management of antiplatelet therapy in patients with coronary artery disease requiring cardiac and noncardiac surgery. <i>Current Opinion in Cardiology</i> , 2014, 29, 553-563.	0.8	8
426	Impact of Cigarette Smoking on P2Y12 Receptor Binding Activity Before and After Clopidogrel Therapy in Patients with Coronary Artery Disease. <i>Journal of Cardiovascular Translational Research</i> , 2014, 7, 47-52.	1.1	8
427	Impact of impaired glucose tolerance on clopidogrel response in patients with coronary artery disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 40, 174-181.	1.0	8
428	Impact of timing from blood sampling to pharmacodynamic assessment on measures of platelet reactivity in patients treated with P2Y12 receptor inhibitors. <i>Thrombosis and Haemostasis</i> , 2016, 116, 1060-1069.	1.8	8
429	In Vitro Pharmacodynamic Effects of Cangrelor on Platelet P2Y12 Receptor-Mediated Signaling in Ticagrelor-Treated Patients. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1374-1375.	1.1	8
430	Should endovascular approach be the first line of treatment for retroperitoneal bleeding with hemodynamic shock following percutaneous intervention? A case series. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 90, 104-111.	0.7	8
431	Systemic inflammatory status is associated with increased platelet reactivity in the early period after acute coronary syndromes. <i>Platelets</i> , 2018, 29, 528-530.	1.1	8
432	The Quest for the Optimal Periprocedural Antithrombotic Treatment Strategy in ACS Patients Undergoing PCI. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1243-1245.	1.2	8

#	ARTICLE	IF	CITATIONS
433	Clopidogrel drug interactions: a review of the evidence and clinical implications. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 1079-1096.	1.5	8
434	Methodologic Considerations on Four Cardiovascular Interventions Trials With Contradictory Results. <i>Annals of Thoracic Surgery</i> , 2021, 111, 690-699.	0.7	8
435	Impaired Clinical Efficacy of Aspirin in Hypoalbuminemic Patients With Diabetes Mellitus. <i>Frontiers in Pharmacology</i> , 2021, 12, 695961.	1.6	8
436	Intracoronary brachytherapy following drug-eluting stent failure It's still not time to hang up the spikes!. <i>Cardiovascular Radiation Medicine</i> , 2003, 4, 171-175.	0.7	7
437	Effects of escalating doses of tirofiban on platelet aggregation and major receptor expression in diabetic patients: Hitting the TARGET in the TENACITY trial?. <i>Thrombosis Research</i> , 2007, 119, 175-181.	0.8	7
438	Investigating the Mechanisms of Hyporesponse to Antiplatelet Approaches. <i>Clinical Cardiology</i> , 2008, 31, 121-127.	0.7	7
439	Pharmacodynamic effects of EV-077: results of an in vitro pilot investigation in healthy volunteers. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 34, 297-299.	1.0	7
440	Impact of aspirin dose on adenosine diphosphate-mediated platelet activities. <i>Thrombosis and Haemostasis</i> , 2013, 110, 777-784.	1.8	7
441	Pharmacodynamic effects of adjunctive high dose atorvastatin on double dose clopidogrel in patients with high on-treatment platelet reactivity depending on diabetes mellitus status. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 37, 427-434.	1.0	7
442	Aspirin Treatment and Outcomes in Patients Undergoing Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2014, 64, 872-874.	1.2	7
443	Transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients. <i>Thrombosis and Haemostasis</i> , 2014, 112, 311-322.	1.8	7
444	Drug-Drug Interactions When Switching Between Intravenous and Oral P2Y12 Receptor Inhibitors. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 130-132.	1.1	7
445	The Rationale for and Clinical Pharmacology of Prasugrel 5 mg. <i>American Journal of Cardiovascular Drugs</i> , 2017, 17, 109-121.	1.0	7
446	Vascular access and antithrombotic therapy in patients with acute coronary syndrome. <i>Lancet</i> , The, 2018, 392, 801-802.	6.3	7
447	Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial. <i>American Heart Journal</i> , 2020, 228, 1-7.	1.2	7
448	MRP4 over-expression has a role on both reducing nitric oxide-dependent antiplatelet effect and enhancing ADP induced platelet activation. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 625-632.	1.0	7
449	The Role of Antiplatelet Therapy in Patients With MINOCA. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 821297.	1.1	7
450	Impact of the ABCD GENE Score on Clopidogrel Clinical Effectiveness after PCI: A Multi-Site, Real-World Investigation. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 146-155.	2.3	7

#	ARTICLE	IF	CITATIONS
451	Late stent thrombosis (> 1 year) following clopidogrel withdrawal after brachytherapy treatment: Need to assess aspirin resistance?. <i>Catheterization and Cardiovascular Interventions</i> , 2004, 62, 39-42.	0.7	6
452	Diagnostic accuracy of quantitative cardiac MRI evaluation compared to stress single-photon-emission computed tomography. <i>International Journal of Cardiovascular Imaging</i> , 2008, 24, 293-299.	0.7	6
453	Pretreatment with Antiplatelet Agents in the Setting of Percutaneous Coronary Intervention. <i>Interventional Cardiology Clinics</i> , 2017, 6, 13-24.	0.2	6
454	Impact of chronic kidney disease on platelet P2Y12 receptor signalling in patients with type 2 diabetes mellitus. <i>Thrombosis and Haemostasis</i> , 2017, 117, 201-203.	1.8	6
455	Pharmacogenomic Testing to Select Antiplatelet Therapy. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1878-1881.	1.2	6
456	Evolving paradigms in antithrombotic therapy for anticoagulated patients undergoing coronary stenting. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2019, 13, 175394471989168.	1.0	6
457	An updated drug profile of ticagrelor with considerations on the treatment of patients with coronary artery disease and diabetes mellitus. <i>Expert Review of Cardiovascular Therapy</i> , 2020, 18, 449-464.	0.6	6
458	Results of an international crowdsourcing survey on the treatment of non-ST segment elevation ACS patients at high-bleeding risk undergoing percutaneous intervention. <i>International Journal of Cardiology</i> , 2021, 337, 1-8.	0.8	6
459	Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 282-293.	1.1	6
460	Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 728-737.	1.4	6
461	Dual antiplatelet therapy duration after percutaneous coronary intervention using drug eluting stents in high bleeding risk patients: A systematic review and meta-analysis. <i>American Heart Journal</i> , 2022, 250, 1-10.	1.2	6
462	Strategies for drug-eluting stent treatment of bifurcation coronary artery disease in the United States: Insights from the eâ€œCypher S.T.L.L.R.Trial. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 73, 890-897.	0.7	5
463	Atopaxar: a review of its mechanism of action and role in patients with coronary artery disease. <i>Future Cardiology</i> , 2012, 8, 503-511.	0.5	5
464	Pharmacodynamic Effects of Ticagrelor Dosing Regimens in Patients on Maintenance Ticagrelor Therapy. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1075-1083.	1.1	5
465	Comparison of Platelet Reactivity in Black Versus White Patients With Acute Coronary Syndromes After Treatment With Ticagrelor. <i>American Journal of Cardiology</i> , 2017, 119, 1135-1140.	0.7	5
466	Atrial fibrillation, with ACS and PCI: walking a tightrope. <i>European Heart Journal</i> , 2019, 40, 1563-1566.	1.0	5
467	Tackling the gap in platelet inhibition with oral antiplatelet agents in high-risk patients undergoing percutaneous coronary intervention. <i>Expert Review of Cardiovascular Therapy</i> , 2021, 19, 519-535.	0.6	5
468	Antiplatelet therapy in percutaneous coronary intervention: latest evidence from randomized controlled trials. <i>Current Opinion in Cardiology</i> , 2021, 36, 390-396.	0.8	5

#	ARTICLE	IF	CITATIONS
469	Pharmacodynamic Effects of Pre-Hospital Administered Crushed Prasugrel in Patients With ST-Segment Elevation Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 1323-1333.	1.1	5
470	Diabetes mellitus: the scary killer haunting silently. <i>EuroIntervention</i> , 2010, 5, 879-881.	1.4	5
471	Pharmacodynamic Profiles of Dual-Pathway Inhibition with or without Clopidogrel versus Dual Antiplatelet Therapy in Patients with Atherosclerotic Disease. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1341-1351.	1.8	5
472	Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 707-716.	1.4	5
473	Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT study. <i>EuroIntervention</i> , 2022, 17, 1330-1339.	1.4	5
474	Antacid Therapy in Coronary Artery Disease and Heart Failure: Proton Pump Inhibitors vs. H2 Receptor Blockers. <i>Cardiovascular Drugs and Therapy</i> , 2024, 38, 181-189.	1.3	5
475	Prognostic Significance of Troponin T Elevation in Patients Without Chest Pain. <i>American Journal of Cardiology</i> , 2008, 102, 668-671.	0.7	4
476	Unravelling the benefit against the risk of long-term dual antiplatelet therapy. <i>Current Opinion in Cardiology</i> , 2011, 26, S22-S30.	0.8	4
477	Pharmacologic Options for Treatment of Ischemic Disease. , 2013, , 83-130.		4
478	Comparison of the pharmacodynamic effects of ranolazine versus amlodipine on platelet reactivity in stable patients with coronary artery disease treated with dual antiplatelet therapy. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 40, 331-339.	1.0	4
479	Ticagrelor versus clopidogrel for recovery of vascular function immediately after successful chronic coronary total occlusion recanalization: A randomized clinical trial. <i>American Heart Journal</i> , 2018, 204, 205-209.	1.2	4
480	Aspirin-Dependent Effects on Purinergic P2Y1 Receptor Expression. <i>Thrombosis and Haemostasis</i> , 2019, 119, 726-734.	1.8	4
481	Ticagrelor or Clopidogrel in Elderly Patients With Myocardial Infarction. <i>Circulation</i> , 2020, 142, 1709-1712.	1.6	4
482	Ticagrelor monotherapy in patients with diabetes mellitus undergoing percutaneous coronary interventions: insights from the TWILIGHT trial. <i>Cardiovascular Research</i> , 2020, 116, e70-e72.	1.8	4
483	When Less Becomes More: Insights on the Pharmacodynamic Effects of Aspirin Withdrawal in Patients With Potent Platelet P2Y ₁₂ Inhibition Induced by Ticagrelor. <i>Journal of the American Heart Association</i> , 2020, 9, e019432.	1.6	4
484	Appraising the contemporary role of aspirin for primary and secondary prevention of atherosclerotic cardiovascular events. <i>Expert Review of Cardiovascular Therapy</i> , 2021, 19, 1097-1117.	0.6	4
485	Ticagrelor With or Without Aspirin in Chinese Patients Undergoing Percutaneous Coronary Intervention: A TWILIGHT China Substudy. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, CIRCINTERVENTIONS120009495.	1.4	4
486	Cangrelor Use Patterns and Transition to Oral P2Y ₁₂ Inhibitors Among Patients With Myocardial Infarction: Initial Results From the CAMEO Registry. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	4

#	ARTICLE	IF	CITATIONS
487	Oral Antiplatelet Therapy in Patients with Diabetes Mellitus and Acute Coronary Syndromes. Trends in Cardiovascular Medicine, 2010, 20, 211-217.	2.3	3
488	Prasugrel. Advances in Cardiology, 2012, 47, 39-63.	2.6	3
489	Antithrombotic Pharmacotherapy in the Elderly: General Issues and Clinical Conundrums. Current Treatment Options in Cardiovascular Medicine, 2012, 14, 57-68.	0.4	3
490	Update on oral antithrombotic therapy for secondary prevention following non-ST segment elevation myocardial infarction. Trends in Cardiovascular Medicine, 2016, 26, 321-334.	2.3	3
491	Intracoronary vs intravenous bivalirudin bolus in ST-elevation myocardial infarction patients treated with primary angioplasty. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 487-496.	0.4	3
492	Platelet Function or Genetic Testing for Guiding De-Escalation of Anti-Platelet Therapy: The Jury is Still Out. Thrombosis and Haemostasis, 2018, 118, 1509-1511.	1.8	3
493	Role of oral anticoagulant therapy for secondary prevention in patients with stable atherothrombotic disease manifestations. Therapeutic Advances in Hematology, 2019, 10, 204062071986147.	1.1	3
494	Anticoagulation, the Unknown of the Antithrombotic Equation After Stenting of an Acute Coronary Syndrome. Journal of the American College of Cardiology, 2019, 73, 775-778.	1.2	3
495	Pooling the Evidence at the Patient Level: End of the Bivalirudin Saga?. Thrombosis and Haemostasis, 2020, 120, 191-193.	1.8	3
496	Duration of Dual Antiplatelet Therapy After PCI. JACC: Cardiovascular Interventions, 2020, 13, 2263-2265.	1.1	3
497	Evidence and Recommendations for Uninterrupted Versus Interrupted Oral Anticoagulation in Patients Undergoing Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2021, 14, 764-767.	1.1	3
498	Systematic Assessment of Online Health Information for Coronary Revascularization. JAMA Internal Medicine, 2021, 181, 1003-1006.	2.6	3
499	Oral antithrombotic therapy for the prevention of recurrent cerebrovascular events. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 383-391.	1.4	3
500	Impact of Timing of Pharmacodynamic Assessment on Platelet Reactivity in Patients Treated With Cangrelor. JACC: Cardiovascular Interventions, 2021, 14, 2410-2412.	1.1	3
501	Short- or long-term outcomes of coronary artery aneurysms occurring after directional coronary atherectomy. Journal of Invasive Cardiology, 2008, 20, 159-60.	0.4	3
502	Clinical Considerations with the Use of Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention. Clinical Cardiology, 2008, 31, 128-135.	0.7	2
503	Platelet inhibitor therapy: Current perspectives and emerging novel agents: Introduction. American Heart Journal, 2008, 156, 1S-2S.	1.2	2
504	Contemporary issues on clopidogrel therapy: a critical appraisal. Internal and Emergency Medicine, 2009, 4, 195-198.	1.0	2

#	ARTICLE	IF	CITATIONS
505	Impact of Adjunctive Cilostazol Therapy Versus High Maintenance Dose of Clopidogrel in Suboptimal Responders With Diabetes Mellitus. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2012, 65, 105-106.	0.4	2
506	Oral trans-mucosal administration of ticagrelor: is this really the future?. <i>Thrombosis and Haemostasis</i> , 2017, 117, 826-828.	1.8	2
507	Response by Angiolillo et al to Letter Regarding Article, "International Expert Consensus Document on Switching Platelet P2Y ₁₂ Receptor Inhibiting Therapies". <i>Circulation</i> , 2018, 137, 2310-2311.	1.6	2
508	Oral Anticoagulation After TAVR in Patients With Atrial Fibrillation. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1577-1579.	1.1	2
509	Reply. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1868-1869.	1.1	2
510	Pharmacodynamics During Transition Between Platelet P2Y ₁₂ Inhibiting Therapies. <i>Interventional Cardiology Clinics</i> , 2019, 8, 321-340.	0.2	2
511	Comparative influence of bleeding and ischemic risk factors on diabetic patients undergoing percutaneous coronary intervention with everolimus-eluting stents. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, 1111-1119.	0.7	2
512	Impact of renal function in high bleeding risk patients undergoing percutaneous coronary intervention: a patient-level stratified analysis from four post-approval studies. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 419-428.	1.0	2
513	Impact of chronic kidney disease on the pharmacodynamic and pharmacokinetic effects of ticagrelor in patients with diabetes mellitus and coronary artery disease. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 452-461.	1.4	2
514	Non-opioid analgesics in patients undergoing percutaneous coronary intervention: hype or hope?. <i>European Heart Journal</i> , 2021, 42, 4037-4039.	1.0	2
515	Antiplatelet strategies in acute coronary syndromes: design and methodology of an international collaborative network meta-analysis of randomized controlled trials. <i>Minerva Cardiology and Angiology</i> , 2021, 69, 398-407.	0.4	2
516	Crushed ticagrelor in comatose patients treated with primary percutaneous coronary intervention. <i>EuroIntervention</i> , 2017, 12, 1681-1683.	1.4	2
517	SCAI Expert Consensus Statement on Sex-Specific Considerations in Myocardial Revascularization. , 2022, 1, 100016.		2
518	Ticagrelor or prasugrel in patients with acute coronary syndrome with off-hour versus on-hour presentation: a subgroup analysis of the ISAR-REACT 5 trial. <i>Clinical Research in Cardiology</i> , 2023, 112, 518-528.	1.5	2
519	Clopidogrel for up to one year after PCI is cost-effective for people with acute coronary syndromes. <i>Evidence-based Cardiovascular Medicine</i> , 2006, 10, 116-118.	0.0	1
520	Introduction. <i>American Journal of Cardiology</i> , 2009, 103, 1A-3A.	0.7	1
521	Targeting Platelet Nitric Oxide Resistance With Ramipril. <i>Journal of the American College of Cardiology</i> , 2012, 60, 895-897.	1.2	1
522	Basics of Antithrombotic Therapy for Cardiovascular Disease. <i>Interventional Cardiology Clinics</i> , 2013, 2, 499-513.	0.2	1

#	ARTICLE	IF	CITATIONS
523	Percutaneous Coronary Interventions in ST-Segmentâ€“Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Interventions</i> , 2013, 6, 593-595.	1.4	1
524	Effect of an Optimized Treatment With Insulin on Platelet Reactivity After Discharge in Patients With an Acute Coronary Syndrome and Hyperglycemia. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2014, 67, 22-27.	0.4	1
525	Management of adjunctive antithrombotic therapy in STEMI patients treated with fibrinolysis undergoing rescue or delayed PCI. <i>Thrombosis and Haemostasis</i> , 2015, 114, 945-957.	1.8	1
526	Acute Coronary Syndromes: Applying Practice Guidelines and Defining the Unmet Need in Clinical Practice. <i>American Journal of Cardiology</i> , 2015, 115, 1A-2A.	0.7	1
527	Reply. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1714-1715.	1.2	1
528	Intracoronary Bivalirudin Bolus in ST-Elevation Myocardial Infarction Patients Treated with Primary Angioplasty: Theoretical Bases, Clinical Experience, and Future Applications. <i>American Journal of Cardiovascular Drugs</i> , 2016, 16, 391-397.	1.0	1
529	Defining a Role for Prasugrel in Patients With Stable Coronary Artery Disease Undergoing Ad Hoc Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 228-230.	1.1	1
530	Tug of War Between Dual and Triple Antithrombotic Therapy in Atrial Fibrillation/PCI Patients With CKD. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1562-1565.	1.1	1
531	Downstream or upstream administration of P2Y12 receptor blockers in non-ST elevated acute coronary syndromes: study protocol for a randomized controlled trial. <i>Trials</i> , 2020, 21, 966.	0.7	1
532	Letter by Angiolillo et al Regarding Article, â€œCangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segmentâ€“Elevation Myocardial Infarction: Primary Results of the FABOLUS FASTER Trialâ€•. <i>Circulation</i> , 2021, 143, e795-e796.	1.6	1
533	Dabigatran-based dual antithrombotic therapy for patients with atrial fibrillation and ST-elevation myocardial infarction undergoing percutaneous coronary intervention. <i>EuroIntervention</i> , 2021, 17, 443-444.	1.4	1
534	Severe, Intolerable Fatigue Associated with Hyperresponse to Clopidogrel. <i>World Neurosurgery</i> , 2021, 156, e374-e380.	0.7	1
535	Patients With Atrial Fibrillation and PCI or ACS. <i>Journal of the American College of Cardiology</i> , 2022, 79, 428-431.	1.2	1
536	Long-term outcome of patients with proximal left anterior descending coronary artery in-stent restenosis treated with a second percutaneous procedure. <i>Journal of Invasive Cardiology</i> , 2005, 17, 218-21.	0.4	1
537	Pre-hospital treatment with crushed versus integral tablets of prasugrel in patients presenting with ST-Segment Elevation Myocardial Infarction â€“ One-year follow-up results of the COMPARE CRUSH trial. <i>American Heart Journal</i> , 2022, , .	1.2	1
538	Raising the loading dose of clopidogrel: aiming at the proper target?: reply. <i>European Heart Journal</i> , 2005, 26, 740-741.	1.0	0
539	Antiagregaci3n oral e intervencionismo coronario percut3neo. <i>Revista Espanola De Cardiologia Suplementos</i> , 2006, 6, 49H-56H.	0.2	0
540	The Impact of Previously Occluded Noninfarct Vessels in Patients With Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2007, 99, 429-430.	0.7	0

#	ARTICLE	IF	CITATIONS
541	Response to Letter Regarding Article, "Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel: Thrombolysis in Myocardial Infarction 38". <i>Circulation</i> , 2009, 119, .	1.6	0
542	Antithrombotic management in patients undergoing coronary stent implantation requiring chronic oral anticoagulation: How to balance safety and efficacy?. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 75, 943-945.	0.7	0
543	Response to Letter regarding Article, "Intensifying Platelet Inhibition With Tirofiban in Poor Responders to Aspirin, Clopidogrel, or Both Agents Undergoing Elective Coronary Intervention: Results From the Double-Blind, Prospective, Randomized Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel Study". <i>Circulation</i> , 2010, 121, .	1.6	0
544	Response to Letter Regarding Article, "Pharmacodynamic Effects of Different Aspirin Dosing Regimens in Type 2 Diabetes Mellitus Patients With Coronary Artery Disease". <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, .	1.4	0
545	Response to Letter Regarding Article, "Antithrombotic Therapy in Patients With Chronic Kidney Disease". <i>Circulation</i> , 2012, 126, .	1.6	0
546	New oral anticoagulants and dual antiplatelet therapy: Focus on apixaban. <i>International Journal of Cardiology</i> , 2016, 225, 154-158.	0.8	0
547	Reply. <i>Journal of the American College of Cardiology</i> , 2017, 69, 250-251.	1.2	0
548	Reply. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2879.	1.2	0
549	Antiplatelet and Anticoagulation Therapy in Percutaneous Coronary Intervention. <i>Interventional Cardiology Clinics</i> , 2017, 6, xi-xii.	0.2	0
550	Percutaneous Interventional Repair of an Intraoperative Right Coronary Artery Tear. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 2464-2465.	1.1	0
551	TCT-643 Antiplatelet therapy with cangrelor in patients undergoing surgery after coronary stent implantation: a real-world bridging protocol experience. <i>Journal of the American College of Cardiology</i> , 2018, 72, B257.	1.2	0
552	Switching antiplatelet therapy in real-world clinical practice. <i>Cardiovascular Revascularization Medicine</i> , 2018, 19, 897-898.	0.3	0
553	Antiplatelet Drugs in the Management of Coronary Artery Disease. , 2019, , 1017-1029.		0
554	Reply. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 2434-2435.	1.1	0
555	Editorial commentary: Evolving paradigms in antithrombotic therapy for patients with coronary artery disease undergoing percutaneous coronary intervention. <i>Trends in Cardiovascular Medicine</i> , 2020, 30, 203-204.	2.3	0
556	Acceso radial frente a femoral y bivalirudina frente a heparina no fraccionada en pacientes vulnerables con síndrome coronario agudo. <i>Revista Espanola De Cardiologia</i> , 2020, 73, 874-876.	0.6	0
557	Reply. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1274-1275.	1.2	0
558	Radial versus femoral and bivalirudin versus unfractionated heparin in vulnerable patients with acute coronary syndromes. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020, 73, 874-876.	0.4	0

#	ARTICLE	IF	CITATIONS
559	Septal perforating artery originating from the ramus intermedius artery. <i>Coronary Artery Disease</i> , 2021, Publish Ahead of Print, e13-e14.	0.3	0
560	Platelet physiology and pharmacology—relevant considerations for patient care. , 2021, , 15-45.		0
561	Antithrombotic pharmacotherapy in patients with established coronary artery disease. , 2012, , 287-301.		0
562	Antithrombotic pharmacotherapy in patients with established coronary artery disease. , 2012, , 287-301.		0
563	Anticoagulation Therapy. Heparins, Factor II and Factor Xa Inhibitors. , 2014, , 59-122.		0
564	Antithrombotic Issues in Women. , 2014, , 321-357.		0
565	Abstract 16668: The Effects of Dabigatran on Fibrin Network Structure and Lysis: A Simple Technique to Monitor Efficacy of Treatment?. <i>Circulation</i> , 2014, 130, .	1.6	0
566	Antiplatelet Therapy Considerations in Women. <i>Cardiovascular Innovations and Applications</i> , 2019, 3, .	0.1	0
567	De-escalation of oral P2Y ₁₂ inhibitors guided by platelet function testing in ACS patients undergoing PCI: impact of diabetes mellitus. <i>EuroIntervention</i> , 2019, 15, e486-e489.	1.4	0
568	Reply. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 230-231.	1.1	0
569	Extensive thrombus of distal anastomosis of saphenous vein graft. <i>Journal of Invasive Cardiology</i> , 2004, 16, 198-200.	0.4	0
570	New antiplatelet agents. <i>Clinical Advances in Hematology and Oncology</i> , 2009, 7, 584-7.	0.3	0
571	Body mass index and efficacy and safety of ticagrelor versus prasugrel in patients with acute coronary syndromes. <i>Revista Espanola De Cardiología (English Ed)</i> , 2021, , .	0.4	0
572	10—Pharmacodynamic profiles of aspirin versus dual-pathway inhibition with either aspirin or clopidogrel among patients with stable atherosclerotic disease. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.0	0
573	Reply. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 903-904.	1.1	0
574	Dual versus triple antithrombotic therapy for atrial fibrillation-ACS/PCI: One size does not fit all. <i>Cardiovascular Revascularization Medicine</i> , 2022, , .	0.3	0